This site is intended for healthcare professionals

This podcast series was initiated and fully funded by Sanofi. The content has been reviewed and approved by the sponsoring company and speakers prior to broadcast. Editorial support for this podcast was provided by OmniaMed Communications. GPnotebook has had no input into the content of this podcast series. © 2022 Sanofi

Time in Range – An alternative or useful addition to HbA1c in type 1 diabetes? (Promotional content from Sanofi)

MAT-IE-2200161 (v1.0) | March 2022
In this episode, Dr Amar Puttanna, Dr Emma Wilmot and Su Down compare and contrast use of HbA1c with Time in Range as a measure of glycaemic control, and discuss the potential implications of their use in clinical practice in the future.

The InRange study is the first randomised controlled trial to use Time in Range as a primary endpoint to compare the second-generation basal insulin analogues Toujeo® (insulin glargine 300 U/mL) and insulin degludec 100 U/mL in people with type 1 diabetes.¹ To access further information, please visit the promotional Sanofi Diabetes website https://www.sanofidiabetes.co.uk/en/products/toujeo/evidence/in-range.

 

Reference

  1. Battelino T et al. Diabetes Ther 2020;11:1017–1027.

UK Prescribing information for Toujeo® (insulin glargine 300 U/mL) can be accessed by clicking here.

Republic of Ireland Prescribing information for Toujeo® (insulin glargine 300 U/mL) can be accessed by clicking here.

Adverse events should be reported.

Great Britain and Northern Ireland reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Sanofi Tel: 0800 090 2314. Alternatively, send via email to [email protected].

Republic of Ireland reporting forms and information can be found at www.hpra.ie; email: [email protected]. Adverse events should also be reported to Sanofi Ireland Ltd. Tel: 01 403 5600. Alternatively, send via email to [email protected].

MAT-IE-2200158 (v1.0) I April 2022

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

This podcast episode is intended for healthcare professionals based in Great Britain, Northern Ireland and the Republic of Ireland

GPnotebook_podcast_white-text

Would you like to receive updates about new podcast episodes by email? (You can unsubscribe at any time)